June 26, 2025 — Prices for pharmaceutical-grade barium sulfate “are up over 40-50% in just a few months,” Brent Willis said, citing a jump from C$7,300 to “over C$10,000” per tonne at Voyageur Pharmaceuticals Ltd.‘s (TSXV: VM) Calgary facility. The surge has only sharpened the company’s resolve to build a mine-to-medicine supply chain that can insulate North America from foreign dependence.

Voyageur’s Frances Creek deposit in British Columbia is the fulcrum of that plan. “China only allowed to export 5% of their pharmaceutical-grade barium sulfate,” Willis noted, underscoring why his team is fast-tracking Frances Creek, whose naturally high purity could displace synthetic alternatives. By pairing the ore body with third-party GMP production today and a future in-house plant, Voyageur aims to realize its motto “from Earth to the bottle.”

The strategy is already translating into distribution footprints. Latin America, grappling with chronic shortages of barium contrast media, became the latest target this week. Voyageur is signing regional wholesalers who will “distribute out to their markets” once product rolls off the Canadian line, positioning the company as a streamlined wholesaler until full vertical integration is achieved. Canada is further ahead: provincial health authorities and private clinics are evaluating initial batches, and a larger run scheduled for August will support “more and more sales being announced.”

In the United States, Voyageur is preparing an FDA 505(b)(2) submission before year-end, a pathway that avoids human trials by improving on existing drugs. “Our goal is to be selling in Q4 of next year into the U.S. market,” Willis said, eyeing radiology’s richest address.

While barium anchors the near term, iodine could unlock even larger margins. In Oklahoma’s Anadarko Basin, Voyageur has wells identified and a partnership with extraction specialist Altillion Inc. to produce 99% pure crystalline I₂. A 200-tonne pilot plant will feed a planned pharmaceutical campus in northern Texas, positioning the company to become “the first I-9 drug producer in the U.S.” and to cut manufacturing costs by as much as 50 percent through full vertical control. “GE Healthcare has tied up the majority of the world’s supply,” Willis explained. “We will be able to secure that supply chain for the North American market.”

Shareholders can expect a busy quarter. Voyageur is “in discussions with multinationals” interested in both iodine and barium assets, an FDA filing is on schedule, and new sales contracts should follow production expansion. “Our vertical-integration strategy is resonating with big-pharma people,” Willis said, betting that as critical mineral demand climbs, owning both the rock and the recipe will pay disproportionate dividends.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSX Venture Exchange, is in development of barium and iodine Active Pharmaceutical Ingredients (API) that offer high-performance and cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast markets, Voyageur aims to become a key player by producing its own barium and iodine. In addition, Voyageur is pursuing the development of new endo fullerene drugs.

Voyageur’s business plan is set to generate cash flow by working with established third-party GMP pharmaceutical manufacturers in Canada thereby ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek Project. Currently, the world’s pharmaceutical barium sulphate is almost entirely synthetically produced resulting in a less effective imaging quality product. Voyageur’s Frances Creek resource boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace that Voyageur believes will replace the current synthetic products with higher quality imaging products.

Voyageur’s ambitious vision is to become the first vertically integrated company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to final production, Voyageur believes it can ensure quality and cost efficiency. With its approach, it embodies the motto of “From the Earth to the Bottle,” highlighting Voyageur’s commitment to responsible sourcing and manufacturing practices.

To learn more about Voyageur Pharmaceuticals Ltd., click here

Disclaimer: Voyageur Pharmaceuticals Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Wednesday, June 25th, at 9 AM EST, featuring Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Voyageur Pharmaceuticals is a Canadian public company developing barium and iodine-based Active Pharmaceutical Ingredients (APIs) for high-performance, cost-effective imaging contrast agents. The company aims to become the first vertically integrated radiology contrast media producer by sourcing and manufacturing its own raw materials. Voyageur owns 100% of the Frances Creek Project, a rare natural barium sulfate deposit. Voyageur works with GMP-certified pharmaceutical manufacturers in Canada to validate its products, with plans to transition into a high-margin domestic producer. The company is also advancing endo fullerene drug development. Voyageur’s strategy emphasizes quality, cost control, and sustainability—embodied in its vision: “From the Earth to the Bottle.”

In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:

• June 23, 2025 – Voyageur and Altillion Forge Landmark Alliance to Establish North America’s First Vertically Integrated Iodine Drug Supply Chain — click here
• June 04, 2025 – Voyageur Enters Revenue Stage with First Commercial Sale of Barium Contrast Agents — click here
• May 12, 2025 – Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President — click here

Here are 5 key data points from their June 23^rd news release titled, “Voyageur and Altillion Forge Landmark Alliance to Establish North America’s First Vertically Integrated Iodine Drug Supply Chain”:

• Strategic MOU Signed: Voyageur Pharmaceuticals signed a non-binding Memorandum of Understanding (MOU) with Altillion Inc. to develop North America’s first vertically integrated iodine-based drug supply chain.
• Iodine Extraction Technology Goals: The collaboration targets 90% iodine recovery with over 99% purity of I₂ crystalline flake; current benchmark pricing is $70/kg or $70,000/tonne.
• Four-Phase Rollout Plan:
  • Phase 1: Bench-scale validation and licensing.
  • Phase 2: 200-tonne/year pilot API plant.
  • Phase 3: Scale up to 1000 tonnes/year.

  • Phase 4: Full sterile injectable drug manufacturing facility in Texas.

• Domestic Infrastructure Development: Plans include building an iodine extraction facility in Oklahoma and a pharmaceutical manufacturing campus in Texas to support vertical integration.
• Funding and Market Positioning: Voyageur is pursuing non-dilutive funding through government programs and strategic partners, addressing North America’s complete reliance on iodine drug imports amid rising global demand and supply constraints.

For more information on Voyageur Pharmaceuticals Ltd., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.

TORONTO, ONTARIO – May 8, 2025 – The Critical Minerals Institute (CMI) is delighted to announce that Brent Willis B.Sc. Eng., President, CEO & Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM | OTCQB: VYYRF) will deliver the Day 1 spotlight address, “Radiology’s Hidden Critical Minerals Crisis—And How Voyageur Is Solving It,” on Tuesday, May 13 (2:55 – 3:10 PM ET) at the National Club in Toronto.

In this presentation, Willis will expose how shortages of pharmaceutical-grade barium and iodine—the unheralded critical minerals that make modern X-ray, CT and MRI imaging possible—have left North American hospitals dependent on vulnerable foreign supply chains, and he will outline Voyageur’s plan to restore domestic security of supply from “the earth to the bottle.”

From Petroleum Engineer to Mine-to-Medicine Pioneer

Calgary-trained petroleum engineer Brent Willis founded Voyageur Minerals in 2013 and guided its evolution into Voyageur Pharmaceuticals, a vertically integrated radiology-drug company that secures its own mineral supply. Under his leadership, the company demonstrated that its flagship Frances Creek barite deposit in British Columbia meets all U.S. Pharmacopeia specifications—giving Voyageur a rare domestic feedstock that matches the purity of synthetic imports while cutting costs and the greenhouse-gas emissions tied to long-distance shipping.

Voyageur has since developed five barium-contrast products—SmoothX, SmoothHD, SmoothLD, VisionHD and VisionLD—all licensed by Health Canada, with additional formulations such as V-Gas™ and iodine agents in the pipeline. Recent clinical studies at Canada Diagnostic Centres validated the product line’s performance, clearing the way for commercial rollout.

Building a North American Radiology Supply Chain

Willis will argue that vertical integration is the only durable answer to radiology’s mineral bottleneck: Voyageur will mine barite at Frances Creek (B.C.) and iodine from its Oklahoma project and Utah claims, refine them into APIs and drugs. — capturing margin at every step while insulating hospitals from geopolitical shocks.

Willis on Why It Matters

“North America is dependent on imports today, so we’re going to be the first domestically produced radiology-drug company,” Willis told InvestorNews earlier this year, stressing the market’s US$6-billion size. “Our strategy is simple: control the mineral, control the molecule, and deliver safer imaging agents from the earth to the bottle.”

Tracy Hughes, Founder & Executive Director of CMI, added:

“Brent is proving that critical minerals security is a health-care issue as much as an industrial one. His mine-to-medicine model offers a blueprint for rebuilding resilient life-science supply chains right here in North America, and our delegates will gain a front-row view of how that blueprint becomes reality.”

CMI Summit IV Event Details

Theme: The War for Critical Minerals and Capital Resources
Dates: Tuesday & Wednesday, May 13–14, 2025
Summit Hours: 8:30 AM – 5:00 PM ET
Registration & coffee: 7:30 – 8:30 AM
Reception: Tuesday, May 13, 5:00 – 6:30 PM — hosted by ArcStone Securities and Investment Corp.
Location: The National Club, 303 Bay Street, Toronto, Ontario, Canada
CriticalMineralSummit.com

To register or secure a CMI Summit IV 2-day Delegates Pass, click here

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the Exchange, is in development of barium and iodine Active Pharmaceutical Ingredients (API) that offer high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast markets, Voyageur aims to become a key player by producing its own barium and iodine, while also pursuing the development of new endo-fullerene drugs. Its business plan is to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring worldwide regulatory validation of its products; as market presence grows, the company intends to transition into a high-margin domestic manufacturer of radiology drugs. Committed to sustainability, Voyageur plans to build state-of-the-art carbon-capture infrastructure using the Rain Cage EDEN™ system and to generate revenue from “advanced carbon production.” The company owns a 100 % interest in the Frances Creek barium-sulphate (barite) project—an exceptionally high-grade resource it believes can replace synthetic pharmaceutical barite with superior imaging quality—and its vision is to become the first vertically integrated radiology-contrast-media drug manufacturer, controlling costs from raw material to final production under the motto “From the Earth to the Bottle.”

About the Critical Minerals Institute

The Critical Minerals Institute (CMI) is a trusted global leader in connecting companies, capital markets, and experts in the critical minerals industry. By combining in-depth research, thought leadership, and extensive industry expertise, CMI provides exclusive insights, invaluable resources, and robust networking opportunities that empower its members to thrive in a rapidly evolving global marketplace. Through collaboration with businesses, governments, and other stakeholders, CMI addresses both the challenges and opportunities within the critical minerals sector, highlighting the value, sustainability, and strategic importance of these essential materials. As a result, CMI ensures its members are equipped to drive innovation, lead in cutting-edge technology, and fuel industrial advancement worldwide.

To secure a CMI Membership, click here or to secure a CMI Summit IV 2-day Delegates Pass, click here

Calgary’s Voyageur Pharmaceuticals turns a humble British Columbia quarry into a bid for global market share

Calgary-based Voyageur Pharmaceuticals Ltd. (TSXV: VM) is wagering that a 120,000-tonne barite deposit in northern British Columbia can do what COVID-era shortages and bruising tariffs could not: break the grip that a handful of multinational giants hold on the world’s contrast-media business.

Today the junior developer announced that it has begun shipping trial lots of five barium-based contrast agents to diagnostic-imaging clinics across Canada and to export markets that accept Health Canada standards, marking its first commercial foray after a small but successful human study at Canada Diagnostic Centres in Calgary. All 24 volunteers produced images that radiologists deemed on par with incumbent products—a green light the company says clears the way for purchase orders later this quarter.

A fragile $6 billion market

Contrast agents—liquids and powders that make blood vessels and organs glow on X-rays, CT scans, and MRIs—form a fast-growing US$6.3 billion market that is projected to top US$10 billion by 2030 as populations age and imaging volumes climb. Yet the sector’s vulnerability was laid bare in 2022 when pandemic shutdowns at a single Shanghai plant choked global supplies of iodinated contrast, forcing some hospitals to ration scans. Prices for iodine raw materials have since more than doubled, according to GE HealthCare, the market leader.

Barium products represent barely US$275 million of the total pie, but they dominate gastrointestinal imaging and rely almost entirely on synthetic ingredients refined overseas. Voyageur’s pitch is simple: mine pharmaceutical-grade barite at its wholly owned Frances Creek project, process it domestically and lock in margins that management says could exceed 70% even at today’s small scale.

From “the earth to the bottle”

Chief executive Brent Willis calls the sample shipments “a transformative moment” that validates the company’s “from the earth to the bottle” strategy. If phase-II trials later this year succeed, Voyageur will file for U.S. Food and Drug Administration clearance under the 505(b)(2) pathway—an abbreviated route that allows companies to rely partly on existing safety data.

Vertical integration is central to the thesis. Natural barite can cost as little as C$650 a tonne to mine and mill, versus as much as C$24,000 for synthetic pharmaceutical-grade material, according to Voyageur’s preliminary economic assessment. By owning the ore body, the company argues, it can insulate itself from the supply shocks that have plagued iodinated agents and offer hospitals a Canadian-sourced alternative.

David versus three Goliaths

The plan pits a micro-cap—Voyageur’s shares last traded at C$0.15 [04/22/2025] on the TSX Venture Exchange, giving it a market value of roughly C$30-million—against deep-pocketed rivals such as GE HealthCare, Germany’s Bayer and France’s Guerbet. Those companies already sell barium brands worldwide and enjoy manufacturing economies of scale.

Voyageur’s immediate challenge is execution: converting positive study data into purchase orders, persuading radiologists to switch suppliers and financing the roughly C$20 million it will need to bring Frances Creek into production. Longer term, the company must prove that natural barite can meet the exacting purity standards regulators impose on ingestible contrast agents—standards that pushed most producers toward synthetics decades ago.

The case for Voyageur

If Voyageur can thread those needles, the payoff could be meaningful. Supplying even a modest share of the barium-contrast market would generate annual revenue far exceeding the company’s current market value. Investors betting on that outcome should remember, however, that mining developments routinely suffer delays, FDA approvals are never guaranteed, and entrenched rivals will not surrender shelf space without a fight.

Still, in a healthcare system increasingly anxious about overseas dependence, a domestically mined answer to a critical imaging input may resonate. After all, diagnostic images are only as clear—and as available—as the contrast agents that power them.

“In our rapidly evolving world, where the scramble for resources often overshadows their profound impact on human life, it is time to shift our focus to a groundbreaking concept: Health Minerals.” — Melissa “Mel” Sanderson, Co-Chair, Critical Minerals Institute (CMI)

Much has been and is being written about critical minerals, with various derivations of the category tossed around – battery metals, defense metals, rare earths. Battery metals include elements such as lithium, graphite, cobalt and silica: defense metals incorporate gallium, germanium, scandium and others, while the variety of rare earths form their own category in part due to their ubiquitous presence in a range of industries and uses.

I propose we need another category: health minerals. Particularly with a rapidly aging global population, mined elements or compounds thereof which are used in diagnosis and treatment of serious diseases such as cancers or crippling conditions such as arthritis have a vigorous demand curve for the foreseeable future. Add the potential some of these materials also hold for gene-level preventative therapies and you begin to see why pharmaceutical companies increasingly are interested in mining.

Let’s take barium for example. If you ever have had a so-called contrast x-ray or MRI where you had to drink the nasty white brew and wait for it to circulate in your system before your scan, you know what barium is. It’s the stuff that enables high-contrast images of internal organs, especially in the gastrointestinal structure but also in brain and lung scans. Recall that during and for up to a year following COVID, there were especially long wait times for MRI scans. This wasn’t just due to a shortage of technicians (although that also was a factor): it stemmed primarily from supply chain disruptions from China, the primary miner of barite, accounting for over 50% of global supply in 2021.

When it comes to treatment decisions for potentially fatal or debilitating diseases, the clearer the image the better the analysis and the better the potential treatment outcomes. So just as with any other critical mineral, the shorter and more reliable the supply chain the better. Especially as tensions between the West and China around critical minerals writ large escalate and the possibility of increasingly limited and certainly more costly access to China-sourced materials casts a worrying shadow over a range of activities, finding alternative sources of key materials is an urgent strategic issue.

So the discovery in Canada of a natural source of pharmaceutical-grade barium sulfate is good news indeed. Voyageur Pharmaceuticals Ltd. (TSXV: VM), the company holding the mining rights, seems poised to disrupt the existing supply chain and potentially seize a commanding market share of the contrast market in the US and Europe.

Even beyond diagnosis, however, the company seems to be exploring possible new treatment options using nanotechnology and fullerene buckies.

What is fullerene? It’s a carbon molecule whose structure resembles the geodesic dome popularized by architect Buckminster Fuller in the 1960’s and whose tetrahedron and octahedron structures are lightweight and incredibly strong. Until recently, fullerenes primarily were extracted from plasma-chamber soot. Working with a company named Rain Cage, Voyageur says it has been able to cost-effectively source fullerenes via carbon capture from tailpipes and stacks in a new form, the endohedral fullerene, aka fullerene buckies. In addition to any other benefits, Rain Cage’s technology would be a huge advance for “green” sustainable mining and combating climate change in the energy sector.

Fundamentally, fullerene buckies’ structure enables the carbon molecule to enfold other materials such as barium at the nanoparticle level, enabling precise imaging targeting the cellular level of individual tumors by injection of the fullerenes. Some research suggests that future applications could expand beyond vastly improved imaging to actual treatment deliveries for a range of cancers including head and neck, lung, bladder and skin.

Voyageur says the Rain Cage process also produces C60 fullerenes. C60 fullerenes have strong antioxidant properties which potentially could combat conditions such as Alzheimer’s, heart disease and cancer.  The anti-inflammatory properties of C60 suggest the possibility of treatments for conditions such as arthritis might be possible at some future point as well.

As research and development (R&D) continues to boldly define new uses and technology begins to make key elements cost-effectively available, opening the door to new diagnostic and treatment possibilities, we might soon begin hearing more about ‘health minerals’ as part of the critical minerals global dialog.

January 27, 2025 — In an enlightening interview on Investor.News, Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM), discussed the indispensable role of barium, specifically barite (barium sulfate), in today’s economy. Highlighting its critical status, Willis explained, “Barite’s number one use is for oil field drilling…it’s got a specific gravity of 4.4 and when you’re drilling a well, you’re adding barite to overcome the pressure so you can continue to drill deeper.” He also emphasized barite’s vital role in the medical field, particularly in radiology, where pharmaceutical-grade barite is scarce and highly valued. “There’s not enough pharmaceutical grade in the world…it’s actually what’s used in the radiology industry is synthetic…it’s called the barium precipitate, and it’s very expensive.”

Willis provided insights into the reasons behind barite’s designation as a critical mineral by authoritative bodies such as the U.S. Geological Survey and the European Union, attributing it to the lack of domestic production and the heavy reliance on imports, mainly from China and India. He noted, “The United States, I think imports well over 80% of their barium needs.” This dependency underscores the strategic importance of barite in maintaining the operational integrity of key industries across the globe.

The conversation also touched on the different listings of barite and barium as critical minerals in various regions, with Willis explaining the cultural variations in its classification. “It’s very critical in all these countries and it’s hitting their critical mineral list because of the dependence these economies need to import these products,” Willis stated. His extensive experience with barite, particularly at Voyageur’s Frances Creek barium sulphate (barite) project, further underscores the mineral’s significant economic potential, where high-grade deposits are leveraged for substantial profitability in the pharmaceutical sector.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API) and intends to offer high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast markets, Voyageur aims to become a key player by producing its own barium, iodine, and new endohedral fullerene drugs (C60). Voyageur has developed five barium contrast products that have Health Canada licenses.

Voyageur’s business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada thereby ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. Currently, the world’s pharmaceutical barium sulphate is almost entirely synthetically produced which management believes results in a less effective imaging quality product. Voyageur’s Frances Creek resource boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace that Voyageur believes will replace the current synthetic products with higher quality lower cost imaging products.

Voyageur’s ambitious vision is to become the first vertically integrated company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to final production, Voyageur intends to ensure quality and cost efficiency. With its approach, it embodies the motto of “From the Earth to the Bottle,” highlighting Voyageur’s commitment to responsible sourcing and manufacturing practices.

To learn more about Voyageur Pharmaceuticals Ltd., click here

Disclaimer: Voyageur Pharmaceuticals Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

Voyageur Pharmaceuticals Launches Barium Product Suite and Advances Iodine Development for Transformational 2025

Voyageur Pharmaceuticals Ltd. (TSXV: VM) recently issued a news release titled “Voyageur Recaps Significant 2024 Achievements and Unveils Plans for Transformational 2025, Including Market Launch for Barium Suite of Products and Advancement of Iodine Suite.” This announcement showcases some of the company’s remarkable milestones and future ambitions. Here are some highlights:

• Signed a Letter of Intent (LOI) with a multinational contrast media company.
• Introduced five new Health Canada-licensed barium contrast products.
• Secured its first sales contract, establishing a foothold in the market.

But that’s not all—market interest in Voyageur Pharmaceuticals is growing as the company emerges as a potential solution to the critical minerals challenge of barium supply. Notably, TSXV: VM has risen 76.47% year to date, reflecting increased investor confidence.

A Transformative Year

2024 was a pivotal year for Voyageur, marked by groundbreaking achievements in product development and strategic advancements. The company is focused on creating high-performance imaging contrast agents using barium and iodine-based Active Pharmaceutical Ingredients (APIs) to address supply chain constraints and enhance diagnostic capabilities. Voyageur’s proprietary product line includes SmoothHD®, SmoothLD®, VisionHD®, VisionLD®, and SmoothX®, along with the innovative VGas effervescent granules, all designed to meet diverse clinical and operational needs in radiology.

In January 2025, Voyageur reached a significant milestone by commencing human testing of its barium contrast product line. Conducted in two phases, this testing evaluates clinical safety, imaging quality, and operational efficiency. Phase one focuses on Canadian radiology centers, paving the way for domestic market entry later in 2025. Phase two will gather data under FDA guidelines to secure U.S. licensing, opening doors to international markets.

A Vertically Integrated Approach

At the core of Voyageur’s strategy is the Frances Creek barium sulfate (barite) project, a rare and high-grade natural resource. This project positions Voyageur to replace synthetic barium sulfate products with superior, cost-effective alternatives. By controlling the supply chain from “the Earth to the Bottle,” the company ensures quality, cost efficiency, and sustainability, reinforcing its competitive advantage.

In addition to barium, Voyageur is advancing its iodine contrast project and pioneering the development of endohedral fullerene molecules, including gadolinium-based agents. These innovations promise to revolutionize diagnostic imaging and theragnostic applications, aligning with the company’s commitment to sustainability. Collaboration with Rain Cage Carbon Inc. further supports this mission by integrating carbon capture technologies into production processes.

Looking Ahead

Led by a seasoned team of experts, Voyageur is poised for significant achievements in 2025. The company’s goals include capturing Canadian market share, securing FDA approvals, and expanding global distribution partnerships. With a robust pipeline, vertically integrated operations, and a strong commitment to sustainability, Voyageur is well-positioned to address critical supply gaps and establish itself as a global leader in radiology drug development.

“Barite is a mineral form of barium sulphate, the most common and widely utilized form of the chemical element, Barium. It serves as a common filler in adhesives, sealants, drilling muds, and similar applications. Its density, low toxicity, and opacity to medical X-rays make it invaluable for imaging the human intestinal tract, as it can pass through without interaction. In all these uses, barite remains economically irreplaceable.” — Jack Lifton, Co-Chair, Critical Minerals Institute (CMI)

Why Barium Matters

Barium and its primary mineral source, barite (barium sulfate), are critical minerals due to their strategic importance across medical and industrial sectors. Barite is explicitly listed as a critical mineral by the U.S. Geological Survey (USGS), the U.S. Critical Raw Materials Resilience (CRSR) list, and the European Union’s critical minerals list. Additionally, barium is classified as a critical mineral in Japan and South Korea, underscoring its global significance.

Key Reasons for Barite and Barium’s Criticality:

1. Medical Use: Barite is essential for producing barium-based contrast agents, indispensable for accurate diagnostics in X-rays and CT scans.
2. Industrial Use: Barite and barium compounds are critical in industries like oil and gas (as weighting agents in drilling muds), electronics, and ceramics.
3. Supply Chain Vulnerabilities: Heavy reliance on imports, mainly from China and India, creates supply risks, highlighting the need for domestic production.
4. Unique Properties: Barite’s high specific gravity, chemical inertness, and opacity make it irreplaceable in various applications, while barium’s reactive properties enable its use in advanced technologies.

The critical importance of barite and barium underlines their role in supporting essential industries, from healthcare to energy, and underscores the urgency of enhancing domestic production to ensure a secure supply chain.

September 17, 2024 — In a recent interview with InvestorNews host Tracy Hughes, Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM), discussed the company’s shift towards creating innovative pharmaceutical formulations and its strategic focus on vertical integration. Voyageur, a Canadian company specializing in barium and iodine Active Pharmaceutical Ingredients (API), is advancing its business model by filing new drug applications under the FDA 505(b)(2) pathway, which allows the use of existing data from similar drugs to expedite approval. “This allows us to go to the FDA with new drugs on our five barium contrast products, which are currently Health Canada approved and set to generate revenue this year in Canada,” Willis explained.

Willis also emphasized Voyageur’s unique position in the contrast media market, which is projected to double in the next decade due to increasing chronic diseases and aging populations. He discussed the company’s Frances Creek project, noting that they have discovered one of the highest-grade barium sulfate deposits, enabling them to produce their own minerals and drugs. “What propels our growth is a tenfold decrease in mineral costs,” Willis noted, referencing the stark cost difference between importing and producing their own barium sulfate. As the company moves toward production, Willis projected significant revenue growth, potentially reaching up to $10 million next year, with the long-term goal of capturing 30% of the market.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the TSXV, is in development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance, cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own barium, iodine, and new endo fullerene drugs.

Voyageur’s business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada, ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs, further expanding its revenue streams.

Voyageur is committed to sustainability and environmental stewardship. Voyageur envisions a future where reducing carbon emissions is the norm, and to achieve this, it will build state-of-the-art carbon-capture infrastructure utilising the Rain Cage EDEN^TM system. By investing in carbon capture energy sources and sustainable manufacturing practices, Voyageur aims to generate revenue from carbon captured “advanced carbon production” to accelerate growth. Voyageur’s unwavering commitment to the environment sets it apart as a pioneer in the industry.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. Currently, the worlds pharmaceutical barium sulphate is almost entirely synthetically produced resulting in a less effective imaging quality product. Voyageur’s Frances Creek resource boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace that will replace the current synthetic products with higher quality imaging products.

Voyageur’s ambitious vision is to become the first vertically integrated company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to the final production, Voyageur ensures quality and cost efficiency. With its approach, it embodies the motto of “From the Earth to the Bottle,” highlighting Voyageur’s commitment to responsible sourcing and manufacturing practices.

To learn more about Voyageur Pharmaceuticals Ltd., click here

Disclaimer: Voyageur Pharmaceuticals Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

InvestorNews is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Thursday, September 12th, at 9 AM EST, featuring Brent Willis, President, CEO, and Director of Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Currently, Voyageur Pharmaceuticals holds 139,473,176 shares outstanding and has a market capitalization of CAD$6,973,659.

In preparation for tomorrow’s InvestorTalk, here are the three most recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:

• September 05, 2024 – Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry — click here
• July 09, 2024 — Voyageur Pharmaceuticals Grants Deferred Share Units — click here
• June 11, 2024 — Testing to Begin of Radiology Endohedral Fullerenes, a Milestone in Nanotechnology & Drug Development — click here

5-Data Points from Voyageur Pharmaceuticals’ most recent news release titled, Voyageur Introduces Five New Barium Contrast Formulations Setting New Standards in Medical Imaging Industry:

1. New Product Line Introduction: Voyageur has developed five new Health Canada licensed barium contrast products under the brands “Vision” and “Smooth,” which are designed to improve medical imaging diagnostics.
2. FDA 505(b)(2) Drug Pathway: The new products will be submitted under the FDA’s 505(b)(2) drug pathway, allowing for faster approvals using existing data, reducing costs and timelines compared to a full New Drug Application (NDA) process.
3. Patient Trials and Clinical Testing: Voyageur has completed test pilot batches and is moving to the final phase of clinical testing, including patient trials for X-ray and CT, expected to last two months, followed by market launches in Canada and internationally.
4. Competitive Shift: By transitioning from generic to advanced formulations, Voyageur aims to create intellectual property, enhancing its competitive position and offering long-term advantages in the medical imaging market.
5. Vertically Integrated Business Model: Voyageur controls its raw materials through its 100% owned Frances Creek barium sulphate project, aiming to be the first fully vertically integrated company in the radiology contrast media market, ensuring cost efficiency and quality from raw material to final product.

(09.11.2024 at 6:00 AM EST, Source)

For more information on Voyageur Pharmaceuticals Ltd., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.

Testing to Begin of Radiology Endohedral Fullerenes, a Milestone in Nanotechnology & Drug Development

Voyageur Pharmaceuticals Ltd. (TSXV: VM) is stepping into a revolutionary phase in the world of medical imaging and nanotechnology. Partnering with Rain Cage Carbon Inc., Voyageur is poised to begin testing on a commercial scale for the encapsulation of gadolinium, bismuth, and iodine within endohedral fullerenes. This advancement follows the first commercial creation of a V@C60 endohedral fullerene, a significant milestone that sets the stage for the development of highly advanced radiology contrast agents.

The work is set to begin later this month, aiming to develop processes to create Gd@C60, Bi@C60, and I@C60 endohedral fullerenes. These compounds promise to enhance the precision and clarity of MRI and CT scans significantly. The potential transformation of medical imaging through these novel compounds cannot be understated, as they offer remarkable stability, bioavailability, and reduced toxicity.

Brent Willis, CEO of Voyageur, expressed his enthusiasm about this groundbreaking initiative, stating that this collaboration with Rain Cage is a pivotal moment in medical science. Willis believes that this is just the beginning of a transformative journey towards revolutionizing healthcare solutions on a global scale. The merger of cutting-edge nanotechnology with pharmaceutical innovation positions Voyageur and Rain Cage at the forefront of medical advancements.

Endohedral fullerenes, which enclose an additional atom, ion, or cluster within their inner sphere, exhibit superior physical and electronic characteristics compared to regular fullerenes. This unique structure provides distinct advantages in radiology, including enhanced image clarity and resolution, targeted delivery, and exceptional stability and bioavailability. For instance, gadolinium endohedral fullerene shows high proton relaxivity and low toxicity, making it a promising candidate for MRI contrast agents.

The synthesis of endohedral fullerenes is complex and requires precise conditions, making them incredibly rare and valuable. However, Rain Cage Carbon has developed a method to create these high-value molecules at scale, marking an industry first. This breakthrough could open new avenues in the development of radiology contrast agents and other medical applications.

Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on developing barium and iodine Active Pharmaceutical Ingredients (API) and high-performance imaging contrast agents. By vertically integrating the barium and iodine contrast market, Voyageur aims to become a key player by producing its own minerals. This strategy not only ensures quality and cost efficiency but also aligns with Voyageur’s commitment to sustainability and environmental stewardship.

The company envisions a future where reducing carbon emissions is standard practice. To achieve this, Voyageur is building state-of-the-art carbon-capture infrastructure utilizing the Rain Cage EDEN^TM system. By investing in carbon capture energy sources and sustainable manufacturing practices, Voyageur aims to accelerate growth and set itself apart as an industry pioneer.

Central to its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project, boasting exceptional grade minerals suitable for the pharmaceutical marketplace. This positions Voyageur to control all primary input costs, from raw material sourcing to final production, embodying its motto of “From the Earth to the Bottle.”

Rain Cage Carbon Inc., a pioneering private Canadian company, is dedicated to decarbonizing industries by capturing CO2 and other emissions and transforming them into advanced carbon. Through its proprietary technology, EDEN™, Rain Cage offers a groundbreaking solution to combat carbon pollution, converting contaminating energy into a recyclable technology with countless applications. Voyageur’s vision of becoming the first vertically integrated company in the radiology contrast media drug market is ambitious yet achievable. By ensuring quality and cost efficiency through control of primary input costs, Voyageur stands ready to revolutionize the medical imaging landscape. As the company embarks on this journey with Rain Cage, the promise of transforming diagnostic imaging and healthcare solutions becomes ever more tangible.